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Abstract
Aim: Apical periodontitis (AP) is correlated with a 
higher risk of developing cardiovascular disease 
(CVD). No data currently exist to suggest that en-
dothelial dysfunction (ED) improves after endodontic 
treatment in patients who have AP, despite a link 
between chronic AP and ED. This study was de-
signed to investigate the expression of early ED 
markers in young adults with chronic AP, before 
and after root canal treatment. 
Methodology: 41 subjects (20 controls and 21 
patients with AP) were examined at enrolment. 
Patients with AP were also assessed 2 and 12 
months after treatment. ENDO-PAT was used to 
measure endothelial flow reserve (EFR) and ELISAs 
were used to assess plasma levels of interleukin 
(IL)-1, IL-6 and TNF-alpha, vasoconstrictor ED en-
dothelin (ET)-1, the circulating endothelial adhesion 
markers intercellular adhesion molecule-1 (ICAM)-1/
CD54 and soluble vascular cellular adhesion mo-
lecule-1 (sVCAM)-1/CD106, soluble CD14, and the 
endothelial leukocyte adhesion molecule E-selectin.
Results: Baseline serum levels of ET-1, ICAM-1, 
E-selectin, IL-1, and sCD14 were elevated in patients 
with AP compared to the control group. There was 
no macroscopic evidence of reduced EFR in either 
group. Treatment for AP was associated with re-
duced inflammation and improved early ED, indic-
ated by a lowering of IL-1, sCD14, ET-1, ICAM-1/
CD54 and E-selectin levels to resemble those of 
control subjects.
Conclusions: Early vascular ED may be driven by 
AP but is reversible with effective endodontic treat-
ment.
Obiettivi: La parodontite apicale (AP) è stata associate 
con un rischio aumentato di patologia cardiovascolare 
(CVDs). Non vi è evidenza che la disfunzione endoteliale 
(ED) migliori a seguito del trattamento endodontico in 
pazienti con AP, nonostante sia stata dimostrata un’as-
sociazione tra AP e ED. Questo studio è stato disegnato 
al fine di valutare l’espressione dei marker precoci di ED 
in giovani adulti con AP cronica, prima e dopo il trat-
tamento endodontico. 
Materiali e metodi: 41 soggetti (20 controlli e 21 pazienti 
con AP) sono stati analizzati all’arruolamento. I pazienti 
con AP sono stati anche valutati a 2 e 12 mesi post-trat-
tamento. ENDO-PAT è stato utilizzato per misurare En-
dothelial flow reserve (EFR) ed ELISA assays sono stati 
utilizzati per valutare il livelli plasmatici di interleuchina 
IL-1, IL-6 e TNF-alpha, il vasocostrittore ED endotelina 
(ET)-1, i marker circolanti di adesione endoteliale, la mo-
lecola di adesione intercellulare (ICAM)-1/CD54 e la mo-
lecola solubile di adesione cellulare vascolare (sVCAM)-1/
CD106, il CD14 solubile, e la molecola di adesione en-
doteliale leucocitaria (E-selectin).
Risultati: I livelli serici al baseline di ET-1, ICAM-1, E-se-
lectin, IL-1, and sCD14 sono risultati aumentati al baseline 
nei pazienti con AP rispetto al gruppo di controllo. Non è 
stata individuata un’evidenza macroscopica di una riduzione 
di EFR in entrambi i gruppi. Il trattamento endodontico 
della AP è risultato associato a una riduzione dell’infiam-
mazione e un miglioramento di ED precoce, abbassando 
i livelli plasmatici di IL-1, sCD14, ET-1, ICAM-1/CD54 e 
E-selectin a quelli dei soggetti del gruppo di controllo.
Conclusioni: La disfunzione vascolare endoteliale precoce 
può essere promossa da AP ed è reversibile con un trat-
tamento endodontico efficace.
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Introduction
Cardiovascular disease (CVD) is becom-
ing an increasing burden in the devel-
oping world due to an evolving profile 
of risk factors (1). Furthermore, it is the 
leading cause of morbidity and mortal-
ity worldwide (2, 3).
The endothelium acts as a modulator of 
vascular tone via the production of re-
laxing factors, such as vasodilator 
prostaglandins, nitric oxide (NO) and 
endothelium-dependent hyperpolariz-
ation factors, as well as contracting 
factors, including endothelin (ET)-1, the 
most potent endogenous vasoconstrictor 
(4-7). The expression of cell-surface ad-
hesion molecules on the endothelium, in 
particular intercellular adhesion mo-
lecule-1 (ICAM-1), soluble vascular cel-
lular adhesion molecule-1 (sVCAM-1), 
and endothelial leukocyte adhesion mo-
lecule (ELAM, also known as E-selectin), 
promotes the binding of circulating 
leukocytes to the endothelium (8) and 
drives endothelial cell activation. The 
development of CVD may be predicted 
by ED and endothelial cell activation. 
Apical periodontitis (AP) occurs in 34-
61% of adults aged 35-45 years old liv-
ing in the developed world and this 
statistic rises with age (9). Inflammation 
associated with AP may enhance an in-
dividual’s risk of developing CVD (10). 
For example, a correlation has been re-
ported between the presence of lesions 
of endodontic origin (LEO) or pulpal 
inflammation and the risk of ischemic 
heart disease (11-14). There are similar-
ities in the immune responses to AP and 
periodontal disease (15), including in-
creased levels of serum soluble CD14 
(sCD14) and C-reactive protein (CRP) that 
occurs as a response to lipopolysacchar-
ide-induced activation of endothelial or 
epithelial cells that do not normally ex-
press membrane-bound CD14 (16). Both 
sCD14 and CRP facilitate systemic in-
flammation. 
Elevated interleukin (IL)-2 and asym-
metric dimethylarginine (ADMA), an 
endogenous inhibitor of nitric oxide 
synthase (NOS), have been reported 
alongside poor NO availability in young 
adult males with AP and early signs of 
ED (17). Although early pre-clinical ED 
is likely to be reversible (18) via modi-
fications in life style, recommended 
drug treatment and the reversal of car-
diovascular risk factors (19), there are 
no data available to indicate that en-
dothelial function is restored following 
endodontic treatment in patients with 
AP. The aim of this study was to invest-
igate vascular and molecular markers of 
early ED before and after root canal 
treatment in patients with chronic AP.
Materials and Methods
Study population. This study was au-
thorized by the Città della Salute e della 
Scienza Ethical Committee (ref. nr. 
0009323; CS2/510). Every patient in-
cluded in the study provided signed, 
written consent. This observational, 
case-controlled clinical trial was de-
signed with a study power of 80%, for a 
sample of 19 paired subjects, assuming 
a 5% significance level. 
Patients who had at least one chronic 
periradicular inflammatory LEO were 
enrolled into the LEO group. Subjects 
were below 35 years of age, of normal 
weight with no medical history of dia-
betes or systemic, oncologic, or immune 
system diseases, not taking current im-
munosuppressive or cortisone drug 
treatment and not undergoing dental 
treatment. Age-matched control sub-
jects were recruited randomly from a 
medical database of the same area. Sub-
jects underwent assessment for CVD 
prior to study initiation and any sub-
jects with CVD were excluded. 
Pulpal and periradicular status were 
determined using vitality thermal and 
electric pulp tests (Diagnostic Unit; Sy-
bron, Orange, CA), palpation, and per-
cussion. Complete periodontal charting 
was recorded. Intra-oral radiographs 
were used to assess the periradicular 
status of any cases of suspected AP us-
ing phosphor sensor imaging plates (20, 
21). At all visits, standardized periap-
ical radiographs were derived using 
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Rinn XCP (Rinn Corp, Elgin, IL) align-
ment system with customized silicone 
bite. Three clinical assistant professors 
analyzed the clinical and radiological 
data and made any diagnoses accord-
ingly. Performance calibration was car-
ried out to minimize any interexaminer 
variability. Examiner concordance was 
analyzed with the Fleiss k score 
(k>0.70). 
Endothelial function. Peripheral arter-
ial tonometry (PAT) was utilized to 
measure endothelial flow reserve (EFR) 
at the distal extremity of the upper 
limbs. This method is not operator-de-
pendent and provides a reproducible 
index of endothelial-dependent vas-
odilation. Finger biosensors measured 
any changes in vasal tone influenced by 
the endothelium using ENDO-PAT2000 
(Itamar Medical, Caesarea, Israel). 
Modifications of vasal tone were pro-
duced by occlusion of the brachial 
artery for 5 minutes with a consequent 
hyperemic response. The opposite arm 
was used as a control.
Blood sample collection. Blood samples 
were collected at enrolment from all 
subjects, and also from the LEO patients 
at 2 and 12 months after apical treat-
ment. Plasma was isolated by centrifu-
gation at 2400 × g for 15 minutes and 
frozen immediately at −80 ° C. 
Biochemical analysis: enzyme-linked 
immunosorbent assay (ELISA). Plasma 
concentrations of IL-1, IL-6, tumor nec-
rosis factor (TNF)-alpha, ET-1, ICAM-
1/CD54, sVCAM-1/CD106, sCD14 and 
E-selectin were determined using 
ELISAs (R&D systems, Minneapolis, 
USA and Sigma Aldrich, Milan, Italy).
Endodontic treatment. Access cavity 
and endodontic pre-treatment were car-
ried out to form a reservoir for irrigant 
solutions following the administration 
of local anesthesia and isolation of rub-
ber dam. A size 10 stainless-steel K-File 
(Dentsply Mai l lefer,  Ba i l lagues, 
Switzerland) was used to carry out root 
canal scouting and a mechanical glide 
path was created using Proglider (Dent-
sply Maillefer, Baillagues, Switzerland). 
The endodontic motor (X-Smart, Dent-
sply Maillefer, Baillagues, Switzerland) 
was set at a 16:1 contra angle using the 
suggested settings (300 rpm on display, 
5 Ncm), at working length (WL). Elec-
tronic WL was recorded with an apex 
locator (Diagnostic Unit, Sybron, Orange 
CA, USA) and checked three times dur-
ing treatment. Initial WL was recorded 
with a size 10 stainless-steel K-File dur-
ing canal scouting and initial glide path 
using an electronic apex locator. A 
second WL was recorded after glide path 
with a size 17 K-File using an electronic 
apex locator and periapical radiographs.
Root canal shaping was carried out us-
ing ProTaper Next™ X1-X2 (Dentsply 
Maillefer, Baillagues, Switzerland) at 
WL. Definitive WL was checked with a 
size 17 K-File after X1 and shaping was 
accomplished with X2 at WL, with 
X-Smart motor set at the suggested set-
tings. A size 10 K-File 0.5 mm beyond 
the apex was used to establish and con-
firm apical patency. Irrigation was per-
formed with a syringe and 30 G en-
dodontic needle using 5% NaOCl 
(Niclor 5, OGNA, Muggiò, Italy) and 
10% EDTA (Tubuliclean, OGNA, Mug-
giò, Italy), for a total of 20 ml each and 
root canals were subsequently dried 
with sterile paper points. Root canals 
were filled immediately following treat-
ment using sealer (Pulp Canal Sealer 
EWT, Kerr Endodontics, Orange, CA, 
USA) and Thermafil technique (Dent-
sply Maillefer, Baillagues, Switzerland), 
according to the manufacturer’s in-
structions. A temporary filling was 
used to seal the access cavity (IRM, 
Dentsply International Inc., Milford, DE 
USA) which was subsequently recon-
structed. Biochemical analysis was car-
ried out in the LEO group at 2 and 
12-month timepoints post-root canal 
treatment and clinical-radiological 
re-evaluation was conducted 12 months 
post-treatment to assess the outcome of 
endodontic treatment (22). Patient out-
comes were categorized as “healed”, 
“healing” and “diseased” according to 
Friedman & Mor (23).
Statistical analysis. Continuous vari-
ables were reported as mean ± standard 
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error of the mean (SEM). The Sha-
piro-Wilk test was used to assess nor-
mality and the Student’s t-test was util-
ized to compare mean values. Statistical 
significance was set at p=0.05 (Stata 
Statistical Software, Release 15, Stata-
Corp. 2017 College Station, TX: Stata-
Corp LLC).
Results
Twenty healthy subjects (mean age 32.07 
years ± 5.28) were assessed at baseline 
and 23 LEO patients (mean age 33.05 
years ± 6.27) were assessed at baseline 
and at 2 and 12 months after treatment. 
Two LEO patients were lost to follow-up 
at 12 months and were excluded from 
the analysis. A favourable outcome was 
reported for 19 LEO patients 12 months 
after treatment (90.5%), with 13 classi-
fied as “healed” and 6 as “healing”. Two 
remained classified as “diseased”. There 
were no statistically significant differ-
ences in clinical parameters or markers 
of systemic inflammation between the 
groups at baseline, except for higher 
serum concentrations of IL-1 (Fig. 1A) 
and sCD14 (Fig. 1B) in the LEO group 
compared to the control group. Concen-
trations of IL-1 (Fig. 1A) and sCD14 (Fig. 
1B) were significantly reduced at 2 and 
12 months after treatment in the LEO 
patients. Post-treatment concentrations 
were comparable to those of the control 
group. Mean EFR, as a measure of en-
dothelial reserve, was similar in the 
control and LEO groups at baseline and 
in the LEO group 2 and 12 months after 
treatment (p>0.05).
ET-1, ICAM-1/CD54 and E-selectin con-
centrations were all significantly higher 
in the LEO group at baseline compared 
to the control group (Fig. 1C, D, E re-
spectively). In each case, concentrations 
had decreased significantly at 2 and 12 
months after treatment. sVCAM-1 levels 
were comparable between the groups at 
baseline and did not change following 
treatment (Fig. 1F). 
With the exception of two non-repon-
ders, there was a positive trend for 
markers of ED to return to concentra-
tions comparable to those of healthy 
controls after root canal treatment in 
the LEO group.
Discussion
Endothelial function has attracted much 
attention in the clinical setting as a reli-
able marker of cardiovascular events in 
humans (24). Low NO levels are con-
sidered a predictor of ED (25), an early 
manifestation of cardiovascular athero-
sclerotic disease. An increase in NOS, an 
endogenous inhibitor (ADMA), and IL-2 
concentrations have been reported in 
young adult males with AP and early 
signs of ED (measured by EFR at the level 
of the distal extremity in the upper limbs 
using PAT) (17). Our study did not fully 
support these results as no differences 
were observed in EFR between the LEO 
and healthy groups. Therefore, we can 
only conclude that any changes in bio-
marker expression observed in this study 
occurred before a detectable alteration in 
vasal tone. 
In our study, the increased expression of 
the potent endogenous vasoconstrictor 
and proinflammatory peptide ET-1 (6), 
was higher in the LEO group than the 
healthy group at baseline, suggesting 
that apical lesions may lead to an in-
crease of serum ET-1 that, in turn, could 
lead to ED. The subsequent post-treat-
ment reduction in serum ET-1 was asso-
ciated with the successful treatment of 
apical lesions. 
The well-defined relationship between 
ED and endothelial cell activation has 
led to the use of E-selectin (26), sVCAM-1 
and ICAM-1 (25) as markers of mortality 
and subclinical atherosclerosis (27). In-
deed, the increased vasoconstriction, 
smooth muscle cell proliferation, plate-
let aggregation, leukocyte adhesion, 
low-density lipoprotein oxidation, and 
matrix metalloproteinase activation as-
sociated with ED and endothelial cell 
activation, can drive atherosclerosis 
and vascular disease (27). In this study, 
baseline levels of ICAM-1 and E-selectin 
were elevated in LEO patients compared 
to healthy controls, and these returned 
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Figure 1
Descriptive statistics (mean 
and standard error of the 
mean) and inferential analysis 
of the tested variables; 
p≤0.0001 LEO group vs. 
healthy subjects at baseline1; 
p≤0.012, 
p<0.0013 and p≤0.00014 LEO 
group 2 or 12 months after 
root canal treatment vs. LEO 
group at baseline 
(A) Interleukin-1; 
(B) soluble sCD14; 
(C) Endothelin-1; 
(D) intercellular adhesion 
molecule ICAM-1; 
(E) E-selectin; 
(F) soluble vascular cellular 
adhesion molecule sVCAM-1. 
LEO=lesion of endodontic 
origin.
to levels equivalent to those observed in 
healthy controls after root canal treat-
ment. Traditional cardiovascular risk 
factors, such as hypercholesterolemia, 
smoking, and oxidative stress, and 
non-traditional risk factors, such as the 
proinflammatory cytokines TNF-α and 
IL-6, are important mediators of en-
dothelial cell activation. The LEO pa-
tients in this study had higher serum 
concentrations of IL-1 and sCD14 than 
the control patients, whereas the serum 
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concentrations of IL-6 and TNF-α did 
not differ between the groups.  
Conclusions
These data suggest that AP is correl-
ated with early vascular ED. This is 
evidenced by elevated serum concen-
trations of ET-1, ICAM-1 and E-selectin 
adhesion molecules and inflammatory 
IL-1 and sCD14, in the absence of any 
macroscopic evidence of decreased 
EFR. In each case, concentrations re-
turned to those observed in healthy 
controls following treatment, suggest-
ing that treatment of AP ameliorates 
early ED. 
Clinical Relevance
Apical periodontitis is correlated to an 
increase of early vascular endothelial 
dysfunction markers in the serum. En-
dodontic therapy returns these to the 
level observed in healthy subjects.
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